About Me
As the son of an engineer and a literature professor, I inherited a passion for a rigorous, number-based understanding of reality and a deep fascination with complex human experiences. This led me to pursue medicine and psychiatry鈥攁nd a quest to apply innovative neuroscientific methods to the search for novel treatments for severe mood disorders, such as depression and bipolar disorder.
I am a professor of psychiatry at 四色AV Grossman School of Medicine. I am also director of clinical research at the Nathan Kline Institute for Psychiatric Research. My research has led to the validation of novel treatments for patients who have severe mood and anxiety disorders, including pharmacological treatments such as ketamine and other glutamatergic drugs, and devices such as novel forms of magnetic stimulation. I also use neuroimaging, neurophysiology, and neurocognitive tests to evaluate structural, biochemical, and functional brain abnormalities in people who have mood disorders, and my research explores how these brain abnormalities may impact clinical treatment.
I have significant clinical and research expertise in the service of patients who have treatment-resistant forms of depression and bipolar disorder. However, my knowledge of treatments and neuroscience would be insufficient if not matched by a passionate desire to understand people鈥檚 unique history and suffering, and to develop mutual trust with each person I am treating. I aim not only to alleviate severe pain and suffering, but also to restore my patients鈥 hope in their futures, and their sense of purpose and effectiveness.
In addition to having been awarded several research prizes, I am honored to have been recognized by my peers as one of 鈥淎merica鈥檚 Top Doctors鈥 in all editions of 鈥淭op Doctors鈥 since 2005, and as one of Castle Connolly鈥檚 鈥淭op Doctors鈥 for psychiatry in the New York Metro Area since 2015.
Conditions and Treatments
Conditions
- acute stress disorder
- anxiety disorders
- attention deficit disorder in adults
- attention deficit hyperactivity disorder
- bipolar disorder
- cognitive disorder
- depression
- generalized anxiety disorder
- mood disorder
- obsessive compulsive disorder
- panic disorder
- post-traumatic stress disorder
- schizophrenia
- social anxiety disorder
Learn more about conditions we treat at 四色AV Langone:
Anxiety Disorders , Attention Deficit Hyperactivity Disorder , Bipolar Disorder , Depression , Post-Traumatic Stress Disorder , SchizophreniaCredentials
Positions
- Professor,
Board Certifications
- American Board of Psychiatry & Neurology - Psychiatry, 2001
Education and Training
- Residency, Massachusetts General Hospital / Harvard Medical School, Psychiatry, 2000
- MD from Carol Davila University, 1992
Is this your profile?
Insurance Plans Accepted
This provider accepts the following insurance plans.
-
Aetna
- AETNA EPO (四色AVLH Employees)
- AETNA EPO (Sunset Park Employees)
- Aetna EPO (AMEX employees)
- Aetna POS (American Express Employer)
-
Anthem Blue Cross Blue Shield
- BCBS EPO (BlackRock Employees)
- BCBS EPO (LICH Employees)
- BCBS PPO (BlackRock Employees)
-
United Healthcare
- United Healthcare (NY University Care Plan)
- United Healthcare Choice (AMEX employees)
- United Healthcare Choice (Blackrock employees)
- United Healthcare Choice (CBS employees)
- United Healthcare Choice (Simon
- United Healthcare EPO (四色AV Langone Health Employees)
- United Healthcare EPO (Sunset Park Employees)
- United Healthcare Indemnity (四色AV Langone Health Employees)
- United Healthcare 四色AV Care (四色AVLH Employees)
- United Healthcare 四色AV Care (Sunset Park Employees)
- United Healthcare Nexus (Amex Employees)
- United Healthcare Plus (四色AV Langone Health Employees)
- United Healthcare Plus (Sunset Park Employees)
- United Healthcare Student Resources (四色AV)
- United Healthcare Value, Advantage and HDHP (New York University employees)
Dan Iosifescu, MD does not accept insurance.
Locations and Appointments
四色AV Langone Psychiatry Associates
1 Park Avenue, 8th Floor, New York, NY 10016
Research My Research
Research Summary
My research is focused on novel pharmacological treatments (such as ketamine, dextromethorphan combinations, and other glutamatergic drugs) and devices (such as photobiomodulation with near infrared light and novel forms of magnetic stimulation) for patients with severe mood and cognitive disorders (such as major depressive disorder, bipolar disorder, Alzheimer鈥檚 disease). In my research I use neuroimaging (MRI, MRS, PET), neuropsychological tests and neurophysiology (quantitative EEG) techniques to evaluate structural, biochemical, and functional brain abnormalities in mood and cognitive disorders and their impact on clinical treatment.
I am a Professor of Psychiatry at the New York University Grossman School of Medicine and Director of the Clinical Research Division at the Nathan Kline Institute for Psychiatric Research. I have over 25 years鈥 experience conducting clinical and translational research in mood and cognitive disorders, funded by the NIH, PCORI and several foundations.
I have authored more than 200 original papers in top peer-reviewed medical journals, more than 50 reviews and book chapters, and more than 150 abstracts. Based on my publications I was recognized by Clarivate as a Highly Cited Researcher (among the top 0.1% of researchers in my field).
I received a series of prestigious research prizes: the NARSAD Young Investigator Award (which I received twice), the Kaplen Award and the Livingston Award from Harvard Medical School, the American Psychiatric Association Young Investigator Award, the NCDEU New Investigator Award, and a NIMH Career Development Award. I was selected as a Member of the American College of Neuropsychopharmacology, a Distinguished Fellow of the American Psychiatric Association, and Treasurer and Board Member of the American Society of Clinical Psychopharmacology.
Academic Contact
Academic office
1 PARK AVENUE 8TH FLOOR
NEW YORK, NY 10016
Phone
Lab Website
Research Interests Timeline
Clinical Trials and Research Studies
-
Transcranial Photobiomodulation for Alzheimer's Disease
-
A Pilot Phase II Open-Label Single-Center Study of Sodium-Glucose Cotransporter-2 Inhibitor Empagliflozin in Major Depressive Disorder
-
Transcranial Near Infrared Radiation and Cerebral Blood Flow in Depression R33
Publications
-
Stern, Emily R; Collins, Katherine A; Bragdon, Laura B; Eng, Goi Khia; Recchia, Nicolette; Coffey, Barbara J; Leibu, Evan; Murrough, James W; Tobe, Russell H; Iosifescu, Dan V; Burdick, Katherine E; Goodman, Wayne K
American journal of psychiatry. 2025 Jan 29; appiajp20240294
-
Wrobel, Anna L; Turner, Megan; Dean, Olivia M; Berk, Michael; Sylvia, Louisa G; Thase, Michael E; Deckersbach, Thilo; Tohen, Mauricio; McInnis, Melvin G; Kocsis, James H; Shelton, Richard C; Ostacher, Michael J; Iosifescu, Dan V; McElroy, Susan L; Turner, Alyna; Nierenberg, Andrew A
Psychiatry research. 2024 Dec ; 342:116197
-
Gaggi, Naomi L; Iosifescu, Dan V
Neuropsychopharmacology. 2024 Nov ; 50(1):314-315